Interpretable ADC-based radiomics models for differentiating hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Read full text
Authors: Yun Zhang, Xiao Yin, Baowen Guo, Hongwu Yang, Zhongjie Huang
Cited by: 0
References: 22

Abstract

Objective: This study aimed to develop interpretable machine learning (ML) models using apparent diffusion coefficient (ADC) radiomics to differentiate hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC). Methods: Radiomic features were extracted from ADC maps of 83 pathologically confirmed HCC and 46 pathologically confirmed ICC patients who underwent MRI examinations. The least absolute shrinkage and selection operator (LASSO) method selected essential features for five ML models: logistic regression (LR), random forest (RF), gaussian naive bayes (GNB), support vector machine (SVM), and k-nearest neighbors (kNN). external validation was performed using 20 HCC and 20 ICC cases from the cancer imaging archive (TCIA) public database. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, accuracy, F1 score, calibration plots, and decision curve analysis (DCA). The best-performing model was interpreted using shapley additive explanations (SHAP). Results: LASSO selected eight features. The models achieved training AUROCs of 0.84-0.95 and internal validation AUROCs of 0.78-0.91. The LR model demonstrated superior performance (training AUROC: 0.95; internal validation AUROC: 0.91; external validation AUROC: 0.85). Moreover, calibration plots and DCA confirmed that this model exhibited the best calibration and clinical utility. SHAP identified wavelet-LLL-firstorder-RootMeanSquared as the most impactful feature. Conclusions: The ADC-based LR model robustly differentiates HCC from ICC, with validated generalizability using public data, offering a promising non-invasive clinical tool.

Fields of Study & Subjects

Radiomics and Machine Learning in Medical Imaging MRI in cancer diagnosis Hepatocellular Carcinoma Treatment and Prognosis

Publication details

Journal / source
Frontiers in Oncology
Volume
16
Pages
1681920–1681920
Publication date
3 February 2026
Language
EN